Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Trial Profile

Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Avelumab (Primary) ; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Paclitaxel; Vinblastine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms AURA trial
  • Most Recent Events

    • 14 Dec 2018 Planned number of patients changed from 220 to 183.
    • 16 Mar 2018 New trial record
    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top